TriangleInavolisib (NCT07368998)
Inavolisib trial for Breast Cancer (NCT07368998). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with ER-positive, HER2-negative advanced breast cancer carrying a qualifying PIK3CA mutation, after progression on CDK4/6-inhibitor plus endocrine therapy. At most one advanced-disease treatment line is allowed; prior chemotherapy for advanced disease is excluded.
The idea: compare two doses of oral inavolisib, each combined with fulvestrant injections into muscle. Inavolisib blocks PI3K growth signaling; fulvestrant blocks estrogen receptors. Both randomized groups receive active treatment. Researchers compare tumor responses and side effects. Endocrine treatment must remain appropriate.
This phase 2 study plans 80 patients. Roche sponsors four recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.